RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo
Authors: Fangchao Gong
Youbin Cui
Liang Chang
Journal: Molecular Medicine Reports (2015)
Discipline: CLINICAL MEDICINE
Keywords: ADAM9; non-small cell lung cancer; cell proliferation; apoptosis; migration
Affiliations: Department of Thoracic Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China.

Abstract:  A disintegrin and metalloproteinase 9 (ADAM9) is a type I transmembrane protein that has been associated with cancer development and metastasis in various types of cancer. However, little is known about its role in non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate whether downregulation of ADAM9 affects cell proliferation, apoptosis, migration and invasion in NSCLC. Thus, a recombinant lentiviral small hairpin RNA expression vector carrying ADAM9 was constructed and infected into the human NSCLC cell line A549. Cell proliferation, apoptosis, migration and invasion in vitro and tumor growth in vivo were determined following downregulation of ADAM9 by RNA interference-mediated ADAM9 gene silencing. It was found that downregulation of ADAM9 expression using an RNA silencing approach in A549 tumor cells significantly inhibited cell proliferation, migration and invasion, induced cell apoptosis in vitro, as well as suppressed in vivo tumor growth in an experimental mouse model of lung metastasis. These data indicate that ADAM9 is potentially an important new therapeutic target for the prevention of tumor growth in NSCLC. 

Retracted: No

PubPeer comments:
 Fig 5A.  Tumor images of mice 21 days following treatment with Lv sh-ADAM9 or Lv sh-NC. ![file] *[left]* Fig 5A from [Zhang et al (2015)] .  Images of tumor tissue with different plasmid treatments collected after sacrification at day 21 . *[right]* Fig 5A from [Chang et al (2016)] .  Images of tumor tissue from the different treatment groups following sacrifice on day 21 of the treatment. ![file] , 
 #1 Thank you very much for your comments. Our team was very shocked when we saw the abnormality of these pictures.We must answer truthfully. Our experiments are all outsourced to biotech companies. Although we have checked the quality of the experimental results many times, as you mentioned, there is a clear overlap between these results. We are very sorry about that.To be honest, we are devastated, shocked beyond belief.This is obviously an unacceptable error. We have restarted the experiments and plan to complete them in three months. If we can t repeat the results, we will contact the MOLECULAR MEDICINE REPORTS to withdraw the manuscript. If we can repeat the results, we will submit all the raw data to the MOLECULAR MEDICINE REPORTS for correction.We re very sorry about the mix-up on our part.Our sincere apologies for any inconvenience caused again! Thank you very much for your insightful comments again. Best regards, Liang Chang , 
 #2  Our experiments are all outsourced to biotech companies. Can you tell us if these biotech companies are part of the structure of Jilin University? The reason I ask is that their work is part of over a hundred papers from faculty at Jilin University (or the associated hospitals), but nowhere else. ,